The global synthetic progestin market is anticipated to grow at a significant CAGR during the forecast period. The major factor for the growth of the market is the rise in Amenorrhea cases. According to a study done in the US, around 5% of menstruating women experience the disease each year. Along with this, the increasing number of breast cancer cases across the globe is expected to fuel the growth of the market during the forecast period.

The increasing cases of Amenorrhea that causes various complications such as the absence of menstrual periods, and an increase in cases of infertility rate in women, uterine dying, breast cancer, etc. will drive the global synthetic progestin market during the forecast period. Progestin has shown promising results in reducing breast pain and in the treatment of uterine tumours and other ailments where synthetic progestin is used in the treatment. Increasing funding initiatives in the field of home health care, and infrastructure development in the health care industry across the globe are some of the major factors that are driving the market during the forecast period.

Various drugs are in the pipeline that are awaiting approval from the US FDA after successful clinical trials in the coming future will further fuel lucrative growth opportunities to the global synthetic progestin market. Some of these drugs include DARE-HRT1, Onapristone, and VOLT02. Some of the key players in the global synthetic progestin market include Alkem Labs, Aquatic Remedies Pvt. Ltd, Biopharma, Blubellpharma, Cadila Pharmaceuticals, Cipla Limited, Estrellas Life Sciences Private Limited, Glenmark Limited, Lupin, Mankind Pharma, Virtus, and many others.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product Type

o By Mode of Delivery

o By Application

    • Regions Covered 

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape -Alkem Labs, Aquatic Remedies Pvt. Ltd, Biopharma, Cadila Pharmaceuticals, Cipla Ltd., Glenmark Ltd.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How players are addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Synthetic Progestin market by Segments

By Product Type

    • Synthetic Progestin

By Mode of Delivery

    • Injectable

    • Suspended Form 

    • Oral 

By Application

    • Menopause

    • Uterine Bleeding 

    • Contraception

    • Cancer

    • Lesions

Global Synthetic Progestin market by Regions

North America       

    • United States 

    • Canada

Europe

    • Germany

    • United Kingdom

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa